Persistent Systems has announced a strategic collaboration with NVIDIA to accelerate the development and deployment of AI-powered solutions for the Healthcare and Life Sciences industry. The partnership aims to help HLS organizations advance computational drug discovery and improve research outcomes using Generative AI and advanced analytics.

Strategic Collaboration Details

The collaboration addresses the increasing pressure on HLS organizations to drive innovation while operating in highly complex, regulated, and data-intensive environments. By combining Persistent's deep domain and engineering expertise with NVIDIA's full-stack AI platform, Life Sciences enterprises can transition from AI experimentation to real-world production deployments in mission-critical environments.

GenMolVS Solution Launch

Persistent has created the Generative Molecules and Virtual Screening (GenMolVS) solution, powered by the NVIDIA BioNeMo platform and NVIDIA NeMo Agent Toolkit. This solution delivers AI-driven molecular simulations that model the physical and chemical properties of molecules using large domain-specific models.

The GenMolVS solution creates intelligent agents to streamline real-time drug discovery workflows through:

• Agentic workflows enabling continuous decisioning across virtual screening
• Candidate prioritization for improved research outcomes
• Downstream experimental planning to guide laboratory experiments
• High-fidelity molecular simulation and virtual screening at scale

Technology Infrastructure and Capabilities

Persistent will leverage NVIDIA AI Enterprise for specialized Life Sciences R&D use cases, including preclinical research. The solution enables high-fidelity molecular simulation and virtual screening at scale, applying AI to model and reason real-world biological and chemical behavior before realization in wet laboratory environments.

The infrastructure includes NVIDIA accelerated computes, servers, NVIDIA AI Enterprise, and NVIDIA NIM microservices to expedite cost-effective development of applications with scalable options and highly accurate AI outputs embedded directly into enterprise workflows.

Industry Impact and Benefits

This simulation-led approach allows Life Sciences organizations to de-risk early-stage discovery, accelerate experimental cycles, and improve downstream success rates in clinical development pipelines. The collaboration enables BioPharma clients to move from months-long experiments to AI-driven discovery in days, using simulation-led intelligence to guide real-world experimentation without compromising scientific rigor or compliance.

Leadership Perspectives

Ganesh Nathella, Executive Vice President and General Manager - HLS Business at Persistent, emphasized that healthcare and life sciences organizations need to discover new therapies faster, as traditional R&D processes are too slow and labor-intensive. John Fanelli, Vice President - Enterprise Software at NVIDIA, highlighted the industry's rapid movement toward AI-driven computational research and discovery to meet urgent global demand for new therapies.

Through this collaboration, Persistent will expand its AI and LLM engineering capabilities by leveraging NVIDIA AI infrastructure, training resources, and certification programs to deliver increasingly sophisticated data and AI platforms for clients.

Persistent Systems Limited conducted virtual investor sessions on March 16, 2026, with two institutional investors as part of its ongoing stakeholder engagement activities. The company notified the stock exchanges about these meetings under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Investor Meeting Details

The company held two separate one-on-one virtual sessions with institutional investors on the same day:

Information Shared

During these investor interactions, Persistent Systems reiterated the information previously shared during its earnings call held on Tuesday, January 20, 2026. The earnings call covered the company's performance for the quarter and nine months ended December 31, 2025. The company specifically clarified that no additional information beyond what was already disclosed in the earnings call was shared with the investors during these sessions.

Regulatory Compliance

The notification was filed under reference number NSE & BSE / 2025-26 / 243, following an earlier intimation dated March 5, 2026. Company Secretary Amit Atre signed the disclosure document, ensuring compliance with regulatory requirements for investor interaction reporting. The company provided a web-link to its analyst presentation and factsheet for Q3FY26 as reference material for the information discussed during the sessions.

These investor meetings represent part of Persistent Systems' regular engagement with institutional stakeholders to maintain transparency and provide updates on business performance and strategic developments.